Navigation and service

You are here:Other risk information

Dolutegravir (Tivicay®, Triumeq®): New study suggests risk of birth defects in babies born to women who were treated for HIV infection

Date 2018.05.22
Active substance dolutegravir

The European Medicines Agency (EMA) is currently evaluating preliminary results from a study which found 4 cases of birth defects.

To the risk information (available in German only)

For details on the review please click on the following link to the homepage of the European Medicines Agency (EMA):

New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir